{"entity":{"id":"nct07169552","kind":"trial","name":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","aka":[],"tldr":"A phase 2 trial of HC010 in non-small-cell lung cancer, run by HC Biopharma Inc., now recruiting.","summary":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is a phase 2 interventional study registered as NCT07169552 by HC Biopharma Inc., with 50 participants planned, started 2025-12-09 and due to reach its primary completion in 2026-12-30. Interventions recorded: HC010.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07169552","url":"https://clinicaltrials.gov/study/NCT07169552"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07169552","phase":"2","setting":"A Multicenter, Single-arm, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of HC010 for Injection in the First-line Treatment of Advanced Non-small Cell Lung Cancer Positive for Programmed Death Ligand-1 (PD-L1)","sponsor":"HC Biopharma Inc.","started":"2025-12-09","startedType":"estimated","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07169552/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}]}}